Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | ASCO 2024: key updates in gastric, colorectal, and hepatocellular cancer treatments

Ian Chau, MD, from Royal Marsden Hospital in London, UK, anticipates key presentations at ASCO 2024, particularly comparing preoperative chemoradiation to therapeutic chemotherapy in resectable gastric cancer, resolving a longstanding debate. Additionally, he looks forward to data on dual checkpoint therapy versus ipilimumab plus nivolumab in colorectal cancer and hepatocellular carcinoma, which promises insights into novel treatment approaches. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.